Transscleral Selective Laser Trabeculoplasty Project

Exclusion Criteria

• •Contraindications to conventional SLT (e.g. corneal abnormalities etc.)
• •Angle Closure Glaucoma
• •Congenital or developmental glaucoma
• •Secondary glaucoma included pigmentary glaucoma
• •Inability to conduct a reliable visual field (defined as fixation losses, false positives or false negatives greater than 33%)
• •Presence of any peripheral anterior synechiae (PAS) in the study eye
• •Any of the following visual field findings using the Humphrey visual field analyzer:
• •* A HFA MD of worse than -12dB
• •* Greater than or equal to 75% of points depressed below the 5% level and greater than or equal to 50% of points depressed below the 1% level on the PD plot
• •* At least 50% of points (i.e., 2 or more) within the central 5 degrees with a sensitivity ≤0dB on the decibel plot
• •* Points within the central 5 degrees of fixation with a sensitivity \<15 dB in both hemifields on the decibel plot
• •* A visual field MD of worse than -12dB in the fellow eye
• •Cup: Disc Ratio more than 0.8
• •More than two hypotensive medications required (combination drops are considered 2 medications)
• •Prior incisional or laser glaucoma surgery (including previous SLT) in the study eye
• •Prior corneal refractive surgery
• •Complicated cataract surgery ≤ 6 months prior to enrollment
• •Presence of visually significant cataract in the opinion of the investigator
• •Clinically significant disease in either eye as determined by the Investigator
• •Clinically significant amblyopia in either eye
• •Dense pigmentation or hemorrhage in the peri-limbal conjunctiva or anterior sclera, Pigmented Pinguecula and Pterigium
• •Women who are pregnant or may become pregnant during the course of the study
• •In the opinion of the investigator the participant might require other ocular surgery within the 12-months, unless for further reduction of their IOP.
• •Concurrent treatment with topical, nasal, inhaled or systemic steroids.
• •Uncontrolled systemic disease that could impact the ability of the participant to attend follow up visits as per the discretion of the investigator
• •Participation in another clinical study
• •Protected or vulnerable subjects (including but not limited to people with impaired intellectual functioning or mental illness, prisoners, terminally ill subjects, immunocompromised…)
• •People not able to read and understand the informed consent
• •People not able to read and understand English language